Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Champions Oncology, Inc. (2I3.F)

5.15
0.00
(0.00%)
As of May 2 at 3:29:01 PM GMT+2. Market Open.
Loading Chart for 2I3.F
  • Previous Close 5.15
  • Open 5.55
  • Bid 4.98 x --
  • Ask 5.15 x --
  • Day's Range 5.15 - 5.55
  • 52 Week Range 3.36 - 11.10
  • Volume 500
  • Avg. Volume 0
  • Market Cap (intraday) 71.209M
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) 12.88
  • EPS (TTM) 0.40
  • Earnings Date Jul 16, 2025 - Jul 21, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

www.championsoncology.com

210

Full Time Employees

April 30

Fiscal Year Ends

Recent News: 2I3.F

View More

Performance Overview: 2I3.F

Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

2I3.F
8.19%
S&P 500 (^GSPC)
3.31%

1-Year Return

2I3.F
14.96%
S&P 500 (^GSPC)
12.29%

3-Year Return

2I3.F
28.47%
S&P 500 (^GSPC)
36.85%

5-Year Return

2I3.F
26.95%
S&P 500 (^GSPC)
100.89%

Compare To: 2I3.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2I3.F

View More

Valuation Measures

Annual
As of 5/2/2025
  • Market Cap

    70.45M

  • Enterprise Value

    73.31M

  • Trailing P/E

    12.96

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.39

  • Price/Book (mrq)

    14.74

  • Enterprise Value/Revenue

    1.42

  • Enterprise Value/EBITDA

    9.85

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.97%

  • Return on Assets (ttm)

    14.64%

  • Return on Equity (ttm)

    376.84%

  • Revenue (ttm)

    58.59M

  • Net Income Avi to Common (ttm)

    6.43M

  • Diluted EPS (ttm)

    0.40

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.2M

  • Total Debt/Equity (mrq)

    117.70%

  • Levered Free Cash Flow (ttm)

    -3.45M

Research Analysis: 2I3.F

View More

Company Insights: 2I3.F

Research Reports: 2I3.F

View More